- 4-year, double-blind, placebo-controlled, randomized clinical trial - Population and treatment: 17 802 patients with normal LDL-C (median 108 mg/dL) and elevated CRP (>2.0 mg/L) randomized to rosuvastatin 20 mg/d or placebo - Primary outcome: Composite of nonfatal MI, nonfatal stroke, hospitalization for unstable angina, revascularization, and confirmed death from CV causes See the article at http://www.theheart.org/article/917181.do

3. JUPITER: Commentary* *All comments from JUPITER hits New Orleans: Landmark study shows statins benefit healthy individuals with high CRP levels (http://www.theheart.org/article/917181.do) "It is a true landmark in preventive cardiology, not only for its findings, but even more so for the challenges it raises to our current strategies for use of cholesterol-lowering medications and to our risk-assessment paradigms." - Dr James Stein "If a patient comes to me with normal LDL-cholesterol levels . . . I tell him to keep doing what he's doing and to go about his business. Now, what happens when that same patient arrives in my office and I know his CRP is elevated? I know that treating him with intensive statin therapy, despite what the guidelines state, is going to cut his risk of cardiovascular morbidity and mortality in half. " - Dr Steven Nissen